The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Seriously Mani you’re getting as bad as Doc D
Cut
Make it all up
Paste
We need a P3 eventually and don’t have the funds so no one has ever said we won’t eventually need to FJS d that in some way.
But we are not all screaming raise now at 5p for trials the company have already told us they can afford.
This isn’t the first time you’ve cried wolf
Get real and stop posting drivel
Doc D
There you go again with your
cut
Making things up
Paste
I’ve said what the company have said
Cut
The Company’s cash resources are sufficient to cover its plans to design and
establish data from an observational study and two investigator-led/Synairgen-
sponsored Phase 2 clinical trials, including manufacture of active and placebo
for use in these trials. Regardless of the outcome of these activities, which are
uncertain, the Company’s available resources are sufficient to cover existing
committed costs and the estimated costs of these activities until at least 30
September 2024
Paste
You really should take up a position in politics your mistruths are so believably well presented.
Thanks Aether, Doc D
I’m doing well, until a scan says otherwise but I guess that’s the world all C patients live in.
I’ve probably got more chance dying of boredom waiting for an update than dying of C
Tell us the detail Mani
How much are they needing to raise in your calculations
What are they raising to cover
How long in your view does the raise need to cover beyond H1
You must have done these calculations to convince yourself of the need for a raise and to satisfy yourself that any announcement is in-line with your views.
You must have calculated where you think the share price will be as that’s an important shareholder impact of any raise and you’re a shareholder
If you can’t tell us these basic things then all you’re doing is shouting raise, raise, raise which of course is what you did last year and as we all know there was no raise.
Hardly credible on this subject
Mani
So a raise in H1 for trials and money to run the company.
Well you keep quoting 5m for 6 months so how long does this raise need to last?
To the end of the trials
To the end of 2025?
How much do they need to raise at 5m for 6 months are we talking a year, 18 months.
5m x 2 or 3, plus the cost of the trials.
Give us the figure you’ve estimated they need?
Obviously when we all congratulate you for being right we want to be sure you are right to say the nearest 5m would seem fair
Tick tock Mani
You’ve been talking about this raise for a year now so you must have calculated
What they need it for
What period of time it’s covering finances for
How much is needed
When they need to do the raise it
Ok I’ll bite Mani
Let’s have the details
When will the fund raise be date please or by what date?
At what share price?
How much will they be raising?
If you’re going to keep posting drivel let’s have some facts from you!
I Should add the company have said the business including the trials are fully funded “UNTIL AT LEAST” autumn.
My guess would be financial jeopardy would not occur until at least 2025. But sometime later this year we will need a financial roadmap and my preference would be earlier rather than into 2025.
All of this might be solved by a JV and who knows Mr Hennings may have been working on one. One thing is for sure we don’t need a commercial director because if the drug succeeds BP will be marketing it
I would agree Spacman that the finances are tight, how tight is impossible to know until we get the update.
The question is will the update include a resolution to that, either in the short or long term, through some funding option / partner involvement / TFG
Will it be partially resolved in the short term by a rise in the share price on news of trials starting, giving the company more financial options.
But this year is pivotal for Synairgen’s survival and Investors holdings. It will be interesting how the market reacts to the upcoming RNS, that may indicate our future prospects.
“ You think somehow UNIVERSAL and Synairgen are engaged in work that all the huge phamaceutical concerns in the world are not interested in and aren't also attemopting to solve - and that somehow - with zero funds and a UNIVERSAL inclusion criteria of anyone with a confirmed respiratory infection - world class ground breaking work is somehow being done ? You're delusional”
Universal Objectives
“To develop phenotypic characterisation of the heterogeneous nature of acute respiratory viral infection and recovery seen in patients admitted to hospital with respiratory symptoms.
(phenotypic analysis - the physical and biochemical characteristics of an organism as determined by the interaction of its genetic constitution and the environment)
Secondary:
To enable accurate stratification of patients for optimal design of future studies of novel pharmacological and non-pharmacological treatment strategies”
I guess if I’m delusional I’m in good company with J&J, Southampton Centre for Biomedical Research
Opinion is great as long as it’s opinion based upon facts
Not wildly subjective and completely at odds with the facts.
These are the facts as laid out by Synairgen’s scientists
“Partnering with high quality researchers and collaborators, to ensure it has the right trial designs.
Equipped with the right diagnostic tools, to be able to identify trial participants potentially most likely to benefit from a broad-spectrum antiviral and SNG001.
This work (including biomarker assessments), together with the substantial body of evidence gathered from clinical trials with SNG001 to date”
So when Doc D posts that Synairgen have everything to clearly identify patients from the Sprinter trial. thats patently wrong using the companies own words.
Just as it’s wrong to say the company does not have enough money for their trials when they’ve announced to the market that they do.
People can and do posts all kinds of opinions on this board . I’m always happy to correct correct them with factual information, however annoying that may be
This is the “opinion” of Doc D who isn’t an expert
“The Sprinter deep dive points really clearly to the cohort. Our patients are identifiable in the hospital without the clever modern profiling asays we seem to be waiting for”
These are the facts as laid out by Synairgen’s scientists who are probably a little more qualified than Doc D
“Partnering with high quality researchers and collaborators, to ensure it has the right trial designs.
Equipped with the right diagnostic tools, to be able to identify trial participants potentially most likely to benefit from a broad-spectrum antiviral and SNG001.
This work (including biomarker assessments), together with the substantial body of evidence gathered from clinical trials with SNG001 to date”
Personally I’ll follow the scientist view but we each have a choice on who to believe
After all how can they discover new patient genome stratification methods compared to huge Pharma resources.
The answer is simple, they do the work that isn’t yet commercially interesting.
Unlike traditional pharmaceuticals, biotech products leverage the intricate workings of living organisms to address a wide range of medical conditions. This approach has paved the way for breakthrough treatments and groundbreaking technologies once considered science fiction